Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

To join this study, participants generally need to be at least 12 years old, though for certain tumors related to Von Hippel-Lindau disease, you must be 18 or older. You must have one of the specific advanced cancers that the study is focusing on, and your doctors must believe you have at least three months to live.

There are also some reasons why you might not be able to join. For example, if you can't swallow pills, have trouble absorbing medicines, or have had another cancer in the last two years that wasn't fully cured. Your breathing and heart health are also important; if you need continuous oxygen or have serious heart problems, you might not be suitable.

Finally, if you've recently had other cancer treatments like chemotherapy, targeted drugs, or biological therapies within the last four weeks (except certain specific drugs for hormone-related issues), you would not be able to participate at this time.

If you decide to take part in this study, you will receive the study medication, belzutifan. You'll have regular hospital visits for check-ups, blood tests, and scans to see how you're responding to the treatment and to monitor your health. These assessments help the doctors understand if the medicine is working and if there are any side effects. The exact number and frequency of visits will be explained by the study team, but they are designed to closely monitor your health and the progress of your cancer. The total duration of your participation will depend on how you respond to the treatment and the study's protocol, but it could involve ongoing treatment and follow-up for several months or longer.